Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm IPO Delayed Until Next Week

NEW YORK (GenomeWeb News) – Amid the volatility in the stock market, the anticipated initial public offering from Fluidigm, which was expected to become effective either Thursday or Friday this week, has been postponed until next week.
 
The South San Francisco, Calif.-based firm still expects to float at $14 to $16 per share and raise net proceeds of roughly $70.8 million, assuming an offering price of $15 per share. If the underwriters’ over-allotment option is exercised in full, Fluidigm could receive net proceeds of $81.9 million.
 
The firm initially filed for the IPO in April. Morgan Stanley is the book-running manager for the offering, with UBS, Leerink Swann, and Pacific Growth Equities acting as co-managers.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.